Ellen Gielen and Gertie Lintjens jointly head CMS‘ practice, which is known for advising on M&A, contentious reimbursement matters, and pricing negotiations. The 'very knowledgeable' Gielen has extensive experience in handling regulatory cases, often involving pharmaceutical and medical device issues, while Lintjens is well versed in handling R&D projects and early access matters involving pharma products. Judith Kok has a solid track record in assisting with biocides matters and distribution issues. Murat Duman joined the group in January 2024.
L'éditorial du Legal 500
Témoignages
Collectés indépendamment par l'équipe de recherche du Legal 500.
‘One of the most broad life sciences teams in the Netherlands covering all aspects of life sciences.’
‘Ellen Gielen has seen it all and thus has both the professional knowledge to help clients achieve their goals as well as the gravitas to guide you there.’
‘Ellen Gielen is great and very knowledgeable. I also enjoy working with Judith Kok.’
Clients clés
- Amgen
- Boston Scientific
- Brocacef
- Carl Zeiss
- Eli Lilly
- Essity
- Johnson & Johnson
- LEO Pharma
- Mölnlycke Health Care
- Netherlands Cancer Institute
Points forts
Represented Eli Lilly in litigation concerning reimbursement of its breast cancer treatment Verzenios.
Advised Carl Zeiss Meditec AG on its agreement to acquire DORC from investment firm Eurazeo SE for EUR 985 million.
Advising Boston Scientific on the development of a logistics center in the Netherlands.
Avocats
Les grands avocats du marché
Avocats associés reconnus parmi les leaders du marché par leurs pairs et leurs clients, régulièrement présents dans les grands dossiers dans lesquels ils sont au premier plan.
Les grands avocats de demain
Jeunes associés disposant d'une reconnaissance montante sur le marché, jouant régulièrement un rôle clé dans des dossiers majeurs.
Responsable de la pratique
Ellen Gielen; Gertie Lintjens
Autres avocats clés
Judith Kok; Renate Bik; Murat Duman